KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) [Yahoo! Finance]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Yahoo! Finance
Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials FRAMINGHAM, Mass. & SALISBURY, England, March 02, 2026 BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and the Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session. The presentations demonstrate a significant shift in how patients manage hereditary angioedema (HAE) attacks when provided with access to sebetralstat, a safe and effective oral on-demand treatment. By reducing barriers to treatment, sebetralstat enabled early intervention which was associated with an improved treatment response. Collectively, the results highlight the potential of oral sebetralstat to help patients treat more attacks, earlier,
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)Business Wire
- KalVista Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness Wire
- KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE GuidelineBusiness Wire
- Most shorted stocks with up to $2B market cap as of mid-February [Seeking Alpha]Seeking Alpha
KALV
Earnings
- 11/10/25 - Beat
KALV
Sec Filings
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- KALV's page on the SEC website